MAP
ALT icon

Moody Aldrich Partners’s Altimmune ALT Stock Holding History

Moody Aldrich Partners’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-157,614
Closed -$610K – 191
2025
Q2 		$610K Buy
+157,614
New +$853K 0.12% 119
2024
Q2 		– Sell
-307,318
Closed -$3.13M – 197
2024
Q1 		$3.13M Buy
+307,318
New +$3.13M 0.53% 80

Other funds holding ALT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Moody Aldrich Partners's ALT Position: Q3 2025 in Review

Moody Aldrich Partners sold out of Altimmune (ALT) in Q3 2025, closing a stake of 157,614 shares — an estimated $610K sold.

Moody Aldrich Partners first reported a position in ALT in Q1 2024 and held it in 2 quarters. The position peaked at $3.13M in Q1 2024. 158 funds tracked by Wall St. Rank hold ALT as of Q3 2025.

  • Moody Aldrich Partners reported no remaining Altimmune position as of Q3 2025 after selling out during the quarter.
  • Moody Aldrich Partners sold 157,614 Altimmune shares in Q3 2025, an estimated $610K.
  • Moody Aldrich Partners first reported a position in Altimmune in Q1 2024 and held it in 2 quarters.
  • Moody Aldrich Partners's Altimmune position peaked at $3.13M in Q1 2024.
  • 158 funds tracked by Wall St. Rank held Altimmune as of Q3 2025.

Based on Moody Aldrich Partners's 13F filing for Q3 2025, filed 21 Oct 2025.